High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Jun 24, 2024

Keywords

ClinConnect Summary

The SARveillance trial is a study looking at two different approaches to monitoring patients who have had surgery for retroperitoneal sarcoma, a type of soft tissue cancer found in the abdomen. The trial aims to compare high-intensity surveillance (more frequent check-ups and imaging) versus lower-intensity surveillance (less frequent check-ups) after the initial surgery. This research is important because it may help doctors determine the best way to keep an eye on patients and catch any potential issues early.

To be eligible for this trial, participants must be adults over 18 who have had their cancer surgically removed (with no remaining cancer at the edges of the tissue removed). Patients with certain conditions, such as those who have metastatic disease (cancer that has spread) or specific types of sarcomas, will not be included. If you join the trial, you can expect regular follow-ups to monitor your health, and you’ll have a say in which type of surveillance you prefer. This study is not yet recruiting participants, but it aims to provide valuable insights into the best ways to support patients after surgery for this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (greater than 18 years)
• • Primary resection
• • Histologically confirmed retroperitoneal, abdominal or pelvic soft tissue sarcoma
• • R0/R1 resection
• • Eligible whether or not the participant undergoes neoadjuvant treatment
• Exclusion Criteria:
• • Metastatic disease at time of randomisation
• • Recurrent, metastatic or residual disease identified on baseline CT imaging (3-4 months post primary resection)
• • Reoperation for recurrent soft tissue sarcoma
• • Re-resection following previous inadequate surgery
• • R2 resection
• • Patients receiving adjuvant therapy that will delay, interrupt or render radiological surveillance unpredictable
• • Uterine sarcomas, gastrointestinal stromal tumour (GIST), fibromatosis, epithelial tumours, multifocal disease, sarcomas of bony origin
• • Patient declined to consent to data sharing with RESAR (unless in a centre contributing via pre-planned IPDMA)